

XORTX Therapeutics shares climb 22.16% after hours as company advances plans for a Canadian gout drug trial.
You can purchase shares of XORTX Therapeutics (NASDAQ:XRTX) through any online brokerage.
Other companies in XORTX Therapeutics’s space includes: Eli Lilly and Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Merck & Co Inc (NYSE:MRK), Novartis AG (NYSE:NVS) and AstraZeneca PLC (NYSE:AZN).
XORTX Therapeutics has a consensus price target of $70.00.
The stock price for XORTX Therapeutics (NASDAQ: XRTX) is $0.8415 last updated November 6, 2026 at 8:56 AM EST.
There are no upcoming dividends for XORTX Therapeutics.
XORTX Therapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for XORTX Therapeutics.
XORTX Therapeutics is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.
XORTX Therapeutics Inc is a clinical-stage pharmaceutical company focused on developing therapies to treat gout and progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications such as...